Chimeric antigen receptor(CAR)-T cell therapy has become a crucial treatment modality for hematopoietic malignancies.Because of the complex treatment procedures of CAR-T cell therapy and its specific severe immune-rel...Chimeric antigen receptor(CAR)-T cell therapy has become a crucial treatment modality for hematopoietic malignancies.Because of the complex treatment procedures of CAR-T cell therapy and its specific severe immune-related adverse events,a multidisciplinary integrated case management approach is necessary.Focusing on how to improve the efficacy and safety of CAR-T cell therapy,we developed this consensus to establish a standardized approach for managing and applying the multidisciplinary teams(MDT)model in CAR-T cell therapy for B-cell non-Hodgkin lymphoma.Full-length version of the consensus can be seen in supplementary file,http://links.lww.com/CM9/B961.展开更多
基金supported by funds from the National Natural Science Foundation of China(Nos.82270233,81830004,and 82070168)National Natural Science Foundation of China Youth Science Foundation Project(No.82200246)+2 种基金Translational Research Grant of NCRCH(No.2020ZKZC04)National Key R&D Program of China(No.2021YFA1100800)Shanghai Municipal Health Commission(No.2020CXJQ02).
文摘Chimeric antigen receptor(CAR)-T cell therapy has become a crucial treatment modality for hematopoietic malignancies.Because of the complex treatment procedures of CAR-T cell therapy and its specific severe immune-related adverse events,a multidisciplinary integrated case management approach is necessary.Focusing on how to improve the efficacy and safety of CAR-T cell therapy,we developed this consensus to establish a standardized approach for managing and applying the multidisciplinary teams(MDT)model in CAR-T cell therapy for B-cell non-Hodgkin lymphoma.Full-length version of the consensus can be seen in supplementary file,http://links.lww.com/CM9/B961.
